Pfizer Inc. (PFE) Valuation
Historical valuation analysis based on 1281 data points (2021-09-10 to 2026-10-16)
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription dru...
Pfizer Inc. (PFE) currently trades at a P/E ratio of 38.90 (historical range: 7.12–40.46, median: 14.96), placing it at the 99th percentile — expensive relative to its history, P/S ratio of 2.65 (range: 1.97–5.48, 62th percentile — above its historical average), EV/EBITDA of 9.97 (range: 6.97–58.86, 32th percentile).
Over the historical period (2021-09-10 to 2026-10-16), Pfizer Inc.'s P/E ratio has expanded by 98% over the observed period (from an average of 11.9 to 23.7).
Pfizer Inc. trades above its historical valuation range, with most metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 38.90 | 14.96 | 99th | expensive relative to its history |
| P/S Ratio | 2.65 | 2.51 | 62th | above its historical average |
| EV/EBITDA | 9.97 | 17.60 | 32th | below its historical average |
| FCF Yield | 6.52% | 7.26% | 38th | above its historical average |
Pfizer Inc. (PFE) Valuation & P/E History
Pfizer Inc. (PFE) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $29.58 with a market capitalization of $168.6 billion. This page provides historical valuation analysis for PFE based on 1281 data points covering 2021-09-10 to 2026-10-16. The P/E ratio of 38.90 is above the historical median of 14.96, placing PFE at the 99th percentile of its valuation range. The P/S ratio of 2.65 compares to a median of 2.51.
PFE Valuation Metrics & Historical Range
The valuation table above shows Pfizer Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether PFE is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests PFE is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Pfizer Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is PFE Overvalued or Undervalued?
Pfizer Inc. trades above its historical valuation range, with most metrics above their median levels. The overall valuation percentile of 64 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive PFE is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full PFE analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.PFE trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.